Recursion delivered a whole‑genome microglia phenomap generated from tens of millions of cell images to Roche and Genentech under their AI drug‑discovery pact, triggering a $30 million milestone payment. The map is intended to accelerate target identification in neurodegenerative disease programs by providing a high‑content atlas of microglial states and perturbation responses. The phenomap expands the partners’ shared computational infrastructure and adds a neuroscience-specific resource to Recursion’s phenomics platform. For large pharma, these datasets promise to shorten discovery cycles and de-risk early target selection; for AI-driven biotech, the payment validates the commercial value of massive phenotypic datasets. Recursion’s delivery underscores how image-based phenomics and AI are being monetized through milestone-driven collaborations, and suggests continued appetite for data-rich discovery tools among pharmas seeking new CNS targets.